Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05388058 · ClinicalTrials.gov registry record · Phase 2
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT05388058: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT05388058 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05388058, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This clinical trial compares topical cannabidiol to placebo in improving chemotherapy-induced peripheral neuropathy, or painful sensations in your hands or feet due to chemotherapy. Peripheral neuropathy is a nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. It usually begins in the hands or feet and gets worse over time. Peripheral neuropathy caused by chemotherapy is called chemotherapy-induced peripheral neuropathy (CIPN). CIPN is commonly seen in patients receiving certain chemotherapy medications and is hard to treat. Medications commonly used to treat CIPN have limited benefits and may cause significant side effects. A small report showed that topical cannabidiol may help treat neuropathy in patients with diabetes. This study is being done to determine if cannabidiol cream can help improve the symptoms of CIPN.
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Cannabidiol
- OTHER Questionnaire Administration
- DRUG Placebo Administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-06-09 |
| Est. Completion | 2023-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05388058
The ClinicalTrials.gov registry entry for NCT05388058 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT05388058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05388058 about?
NCT05388058 is a clinical study titled "Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy". This clinical trial compares topical cannabidiol to placebo in improving chemotherapy-induced peripheral neuropathy, or painful sensations in your hands or feet due to chemotherapy. Peripheral neuropathy is a nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in differe...
What is the current status of trial NCT05388058?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2022-06-09. Estimated completion is 2023-07-28.
What interventions are being tested in trial NCT05388058?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Cannabidiol (DRUG), Questionnaire Administration (OTHER), Placebo Administration (DRUG).
Who is sponsoring clinical trial NCT05388058?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.